Can flavonoids from honey alter multidrug resistance?

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Multidrug resistance (MDR) in cancer chemotherapy is a significant challenge, often mediated by ATP-binding cassette (ABC) transporter proteins like P-glycoprotein (P-gp).
• P-gp actively effluxes chemotherapy drugs from cancer cells, reducing their efficacy and bioavailability.
• Developing effective chemosensitizers to overcome P-gp-mediated MDR is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To investigate the potential of honey, rich in polyphenolic flavonoids, as a novel inhibitor of P-glycoprotein (P-gp).
• To explore the dual-mode mechanism by which flavonoids interact with P-gp to reverse multidrug resistance (MDR).

Main Methods:

• Literature review and analysis of known flavonoid-P-gp interactions.
• Hypothesizing the inhibitory effects of common honey flavonoids (chrysin, genistein, quercetin, etc.) on P-gp ATPase activity and drug efflux.
• Proposing a dual-mode inhibition mechanism involving ATPase inhibition and competitive substrate interaction.

Main Results:

• Common flavonoids found in honey, such as chrysin, genistein, and quercetin, have demonstrated interactions with P-gp transporters.
• Flavonoids exhibit a dual-mode action: inhibiting P-gp ATPase activity and acting as competitive substrates, thereby enhancing drug efficacy.
• This dual mechanism suggests flavonoids can effectively reverse P-gp-mediated multidrug resistance.

Conclusions:

• Honey, due to its rich flavonoid content, is a promising natural candidate for a chemosensitizer to combat P-gp-mediated multidrug resistance (MDR) in cancer.
• The dual-mode interaction of flavonoids with P-gp offers a potentially enhanced therapeutic index.
• Utilizing honey as a chemosensitizer could reduce the financial burden associated with developing novel MDR-reversing agents.